A New, Active Metabolite of ‘Miracil D’
Generate an AI Snapshot to get a quick, structured summary of this paper.
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The latest and most thorough investigation was carried out by Strufe3, who found that the drug underwent extensive metabolic transformation in all species studied and none of the above ‘Miracil D’ derivatives qualified as the elusive active agent.
Abstract
'MIRACIL D' ('Lucanthone', I)1 is an orally active schistosomicidal drug which is of limited value in the treatment of human S. haematobium and S. mansoni infections2. For a variety of reasons it was thought that the effects of this agent were mediated through a therapeutically more active metabolite. A number of abortive attempts have been made to identify and isolate this substance. The latest and most thorough investigation was carried out by Strufe3, who found that the drug underwent extensive metabolic transformation in all species studied. The major urinary metabolite in the mouse proved to be the sulphone (II), while the monkey furnished the sulphoxide (III) and man excreted a 'chromopeptide', a complex of III with polypeptide. It was concluded that none of the above 'Miracil D' derivatives qualified as the elusive active agent.